Walaa E. Kattan

Walaa E. Kattan

Auto-generated profile, based on publicly available information

Walaa E. Kattan

Department of Genetics, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2018 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
MZMinjing Zou
Minjing Zou
AAAli S Alzahrani
Ali S Alzahrani
AAAli Al-Odaib
Ali Al-Odaib
MAMohammad A Alqahtani
Mohammad A Alqahtani
OBOmer Babiker
Omer Babiker
YSYufei Shi
Yufei Shi
Context Congenital hypothyroidism (CH) is the most common neonatal endocrine disorder, affecting one in 3000-4000 newborns. Since the introduction of a newborn screening program in 1988, more than 300 cases have been identified. The underlying genetic defects have not been systematically studied. Objective To identify mutation spectrum of CH-causing genes. Methods Fifty-five patients from 47 families were studied by next-generation-exome sequencing. Results Mutations were identified in 52.7% of patients (29/55) in the following 11 genes: TG, TPO, DUOX2, SLC26A4, SLC26A7, TSHB, TSHR, NKX2-1, PAX8, CDCA8, and HOXB3. Among 30 patients with thyroid dyshormonogenesis, biallelic TG mutations were found in 12 patients (40%), followed by biallelic mutations in TPO (6.7%), SLC26A7 (6.7%), and DUOX2 (3.3%). Monoallelic SLC26A4 mutations were found in two patients, one of them co-existing with two tandem biallelic deletions in SLC26A7. In 25 patients with thyroid dysgenesis, biallelic mutations in TSHR were found in 6 patients (24%). Biallelic mutations in TSHB, PAX 8, NKX2-1, or HOXB3 were found once in four different patients. A monoallelic CDCA8 mutation was found in one patient. Most mutations were novel including three TG, two TSHR, and one in each of DUOX2, TPO, SLC26A7, TSHB, NKX2-1, PAX8, CDCA8, and HOXB3. SLC26A7 and HOXB3 were novel genes associated with thyroid dyshormonogenesis and dysgenesis, respectively. Conclusions TG and TSHR mutations are the most common genetic defects in Saudi CH patients. The prevalence of other disease-causing mutations is low, reflecting the consanguineous nature of the population. SLC26A7 mutations appear to be associated with thyroid dyshormonogenesis.

28 January 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
JLJunchen Liu
Junchen Liu
RHRansome van der Hoeven
Ransome van der Hoeven
WKWalaa E. Kattan
Walaa E. Kattan
JCJeffrey Chang
Jeffrey Chang
DMDina Montufar-Solis
Dina Montufar-Solis
JHJohn F Hancock
John F Hancock
Oncogenic KRAS expression generates a metabolic dependency on aerobic glycolysis, known as the Warburg effect. We report an effect of increased glycolytic flux that feeds into glycosphingolipid biosynthesis and is directly linked to KRAS oncogenic function. High resolution imaging and genetic approaches show that a defined subset of outer leaflet glycosphingolipids, including GM3 and SM4, is required to maintain KRAS plasma membrane localization, with GM3 engaging in cross-bilayer coupling to maintain inner leaflet phosphatidylserine content. Thus, glycolysis is critical for KRAS plasma membrane localization and nanoscale spatial organization. Reciprocally oncogenic KRAS selectively upregulates cellular content of these same glycosphingolipids, whose depletion in turn abrogates KRAS oncogenesis in pancreatic cancer models. Our findings expand the role of the Warburg effect beyond ATP generation and biomass building to high-level regulation of KRAS function. The positive feedforward loop between oncogenic KRAS signaling and glycosphingolipid synthesis represents a vulnerability with therapeutic potential.

13 December 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
WKWalaa E. Kattan
Walaa E. Kattan
JLJunchen Liu
Junchen Liu
DMDina Montufar-Solis
Dina Montufar-Solis
HLHong Liang
Hong Liang
BBBhargavi Brahmendra Barathi
Bhargavi Brahmendra Barathi
JHJohn F Hancock
John F Hancock
Significance: Exquisite lipid-binding specificity for phosphatidylserine (PtdSer) is hardwired into the structure of the KRAS C-terminal plasma membrane (PM) anchor. This renders KRAS–PM localization and hence biological function potentially vulnerable to perturbations of PM PtdSer content. Here, we show that all components of the recently described lipid transport machinery that maintain PM PtdSer content are indeed required to support KRAS oncogenic function. In this context, we demonstrate that the enzyme, PI4KIIIα, in particular has merit as a druggable target for inhibitingKRAS-dependent tumors. More generally, we provide insight into how PM phospholipids can regulate oncogene signaling and how PM lipid composition may be successfully targeted to exploit tumor vulnerabilities.

26 August 2019 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
WKWalaa E Kattan
Walaa E Kattan
WCWei Chen
Wei Chen
XMXiaoping Ma
Xiaoping Ma
TLTien Hung Lan
Tien Hung Lan
DHDharini van der Hoeven
Dharini van der Hoeven
JHJohn F Hancock
John F Hancock
The small GTPase KRAS, which is frequently mutated in human cancers, must be localized to the plasma membrane (PM) for biological activity. We recently showed that the KRAS C-terminal membrane anchor exhibits exquisite lipid-binding specificity for select species of phosphatidylserine (PtdSer). We, therefore, investigated whether reducing PM PtdSer content is sufficient to abrogate KRAS oncogenesis. Oxysterol-related binding proteins ORP5 and ORP8 exchange PtdSer synthesized in the ER for phosphatidyl-4-phosphate synthesized in the PM. We show that depletion of ORP5 or ORP8 reduced PM PtdSer levels, resulting in extensive mislocalization of KRAS from the PM. Concordantly, ORP5 or ORP8 depletion significantly reduced proliferation and anchorage-independent growth of multiple KRAS-dependent cancer cell lines, and attenuated KRAS signaling in vivo. Similarly, functionally inhibiting ORP5 and ORP8 by inhibiting PI4KIIIα-mediated synthesis of phosphatidyl-4-phosphate at the PM selectively inhibited the growth of KRAS-dependent cancer cell lines over normal cells. Inhibiting KRAS function through regulating PM lipid PtdSer content may represent a viable strategy for KRAS-driven cancers.

1 July 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KDKorcan Demir
Korcan Demir
WKWalaa E Kattan
Walaa E Kattan
MZMinjing Zou
Minjing Zou
EDErdem Durmaz
Erdem Durmaz
HBHuda BinEssa
Huda BinEssa
YSYufei Shi
Yufei Shi
The CYP27B1 gene encodes 25-hydroxyvitamin D-1α-hydroxylase. Mutations of this gene cause vitamin D-dependent rickets type 1A (VDDR-IA, OMIM 264700), which is a rare autosomal recessive disorder. To investigate CYP27B1 mutations, we studied 8 patients from 7 unrelated families. All coding exons and intron-exon boundaries of CYP27B1 gene were amplified by PCR from peripheral leukocyte DNA and subsequently sequenced. Homozygous mutations in the CYP27B1 gene were found in all the patients and heterozygous mutations were present in their normal parents. One novel single nucleotide variation (SNV, c.1215 T>C, p.R379R in the last nucleotide of exon 7) and three novel mutations were identified:, a splice donor site mutation (c.1215+2T>A) in intron 7, a 16-bp deletion in exon 6 (c.1022-1037del16), and a 2-bp deletion in exon 5 (c.934_935delAC). Both c.1215 T>C and c.1215+2T>A were present together in homozygous form in two unrelated patients, and caused exon 7 skipping. However, c.1215 T>C alone has no effect on pre-mRNA splicing. The skipping of exon 7 resulted in a shift of downstream reading frame and a premature stop codon 57 amino acids from L380 (p.L380Afs*57). The intra-exon deletions of c.1022-1037del16 and c.934_935delAC also resulted in a frameshift and the creation of premature stop codons at p.T341Rfs*5, and p.T312Rfs*19, respectively, leading to the functional inactivation of the CYP27B1 gene. Clinically, all the patients required continued calcitriol treatment and the clinical presentations were consistent with the complete loss of vitamin D1α-hydroxylase activity. In conclusion, three novel mutations have been identified. All of them caused frameshift and truncated proteins. The silent c.1215 T>C SNV has no effect on pre-mRNA splicing and it is likely a novel SNP. The current study further expands the CYP27B1 mutation spectrum.

6 April 2017 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
AGAyla Guven
Ayla Guven
RARoua A. Al‐Rijjal
Roua A. Al‐Rijjal
HBHuda A. BinEssa
Huda A. BinEssa
DDDurmuş Dogan
Durmuş Dogan
YKYılmaz Kor
Yılmaz Kor
YSYufei Shi
Yufei Shi